Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison.
Direct oral anticoagulants
dual antiplatelet therapy
myocardial infarction
percutaneous coronary intervention
total thrombus analysis system
Journal
Platelets
ISSN: 1369-1635
Titre abrégé: Platelets
Pays: England
ID NLM: 9208117
Informations de publication
Date de publication:
17 Feb 2022
17 Feb 2022
Historique:
pubmed:
16
4
2021
medline:
30
3
2022
entrez:
15
4
2021
Statut:
ppublish
Résumé
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is prescribed for 1-year after myocardial infarction. Two clinical strategies are considered at 1-year: continuation of DAPT or "Dual Pathway" (DP), using aspirin and rivaroxaban. No head-to-head comparative studies exist. In our
Identifiants
pubmed: 33856269
doi: 10.1080/09537104.2021.1904134
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM